Who owns ONKURE THERAPEUTICS INC-A?
- Ticker: OKUR
- CUSIP Number: 68277q105
Tip: Access positions for across all investors
Analyze quarterly positions in Onkure Therapeutics Inc-a with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Onkure Therapeutics Inc-a stock
Who bought or sold ONKURE THERAPEUTICS INC-A this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Cormorant Asset Management | 1.8M | $7.9M | 0% | Mar 2025 |
|
| Acorn Capital Advisors | 1.4M | $5.1M | 0% | Mar 2025 |
|
| Citadel Advisors | 1.1M | $4.4M | -1% | Mar 2025 |
|
| Perceptive Advisors | 1.0M | $4.3M | 0% | Mar 2025 |
|
| Vanguard Group | 707k | $3.0M | 0% | Mar 2025 |
|
| Vestal Point Capital | 635k | $2.7M | 0% | Mar 2025 |
|
| Deep Track Capital | 524k | $2.3M | 0% | Mar 2025 |
|
| StepStone | 492k | $2.1M | 0% | Mar 2025 |
|
| NEA Management Company | 479k | $2.1M | 0% | Mar 2025 |
|
| Highbridge Capital Management | 439k | $1.9M | 10% | Mar 2025 |
|
| Tang Capital Management | 400k | $1.7M | 36% | Mar 2025 |
|
| Carlyle | 270k | $1.2M | 0% | Mar 2025 |
|
| Prosight Management | 187k | $802k | 193% | Mar 2025 |
|
| Shay Capital | 151k | $650k | 906% | Mar 2025 |
|
| Cantor Fitzgerald, L. P. | 131k | $562k | 266% | Mar 2025 |
|
| BlackRock | 89k | $383k | -5% | Mar 2025 |
|
| Geode Capital Management | 86k | $371k | 13% | Mar 2025 |
|
| Sphera Funds Management | 81k | $346k | -8% | Mar 2025 |
|
| Boothbay Fund Management | 78k | $336k | 0% | Mar 2025 |
|
| Nantahala Capital Management | 54k | $233k | -1% | Mar 2025 |
|
| Aldebaran Capital | 45k | $194k | -1% | Mar 2025 |
|
| Renaissance Technologies | 42k | $180k | -12% | Mar 2025 |
|
| Two Sigma Advisers | 28k | $119k | 94% | Mar 2025 |
|
| Two Sigma Investments | 27k | $117k | 100% | Mar 2025 |
|
| Bridgeway Capital Management | 25k | $108k | 100% | Mar 2025 |
|
| Northern Trust | 19k | $83k | 0% | Mar 2025 |
|
| Qube Research & Technologies | 19k | $80k | 100% | Mar 2025 |
|
| ADAR1 Capital Management | 10k | $43k | 100% | Mar 2025 |
|
| Barclays | 6.8k | $29k | -23% | Mar 2025 |
|
| Wells Fargo & Company | 3.6k | $16k | 123% | Mar 2025 |
|
| China Universal Asset Management | 2.5k | $11k | -5% | Mar 2025 |
|
| Tower Research Capital | 2.2k | $9.6k | 1% | Mar 2025 |
|
| Mirae Asset Global Investments | 423.00 | $1.9k | 0% | Mar 2025 |
|
| Gf Fund Management | 313.00 | $1.3k | 18% | Mar 2025 |
|
| Bnp Paribas Arbitrage, Snc | 297.00 | $1.3k | 26% | Mar 2025 |
|
| UBS Group | 280.00 | $1.2k | -87% | Mar 2025 |
|
| Jpmorgan Chase & Co | 231.00 | $992.999700 | -31% | Mar 2025 |
|
| Citigroup | 190.00 | $836.000000 | 86% | Mar 2025 |
|
| Group One Trading | 56.00 | $241.001600 | -81% | Mar 2025 |
|
| Royal Bank of Canada | 32.00 | $0 | -26% | Mar 2025 |
|
| MAI Wealth Advisors | 6.00 | $25.999800 | 0% | Mar 2025 |
|
Who sold out of Onkure Therapeutics Inc-a?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Altium Capital Management | Dec 2024 | 218k | $1.9M |
| Millennium Management | Dec 2024 | 144k | $1.2M |
| 683 Capital Management | Dec 2024 | 43k | $373k |
| Cubist Systematic Strategies | Dec 2024 | 21k | $177k |
| XTX Topco | Dec 2024 | 19k | $160k |
| Susquehanna International | Dec 2024 | 14k | $122k |
| OMERS Administration Corporation | Dec 2024 | 12k | $104k |
| Advisor Group Holdings | Dec 2024 | 152.00 | $1.3k |